127 related articles for article (PubMed ID: 26903551)
1. Institutional prevalence of malignancy of indeterminate thyroid cytology is necessary but insufficient to accurately interpret molecular marker tests.
Valderrabano P; Leon ME; Centeno BA; Otto KJ; Khazai L; McCaffrey JC; Russell JS; McIver B
Eur J Endocrinol; 2016 May; 174(5):621-9. PubMed ID: 26903551
[TBL] [Abstract][Full Text] [Related]
2. Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate Cytology: A Prospective Blinded Multicenter Study.
Steward DL; Carty SE; Sippel RS; Yang SP; Sosa JA; Sipos JA; Figge JJ; Mandel S; Haugen BR; Burman KD; Baloch ZW; Lloyd RV; Seethala RR; Gooding WE; Chiosea SI; Gomes-Lima C; Ferris RL; Folek JM; Khawaja RA; Kundra P; Loh KS; Marshall CB; Mayson S; McCoy KL; Nga ME; Ngiam KY; Nikiforova MN; Poehls JL; Ringel MD; Yang H; Yip L; Nikiforov YE
JAMA Oncol; 2019 Feb; 5(2):204-212. PubMed ID: 30419129
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of ThyroSeq v2 performance in thyroid nodules with indeterminate cytology.
Valderrabano P; Khazai L; Leon ME; Thompson ZJ; Ma Z; Chung CH; Hallanger-Johnson JE; Otto KJ; Rogers KD; Centeno BA; McIver B
Endocr Relat Cancer; 2017 Mar; 24(3):127-136. PubMed ID: 28104680
[TBL] [Abstract][Full Text] [Related]
4. Single Institution Experience with Afirma and Thyroseq Testing in Indeterminate Thyroid Nodules.
Gortakowski M; Feghali K; Osakwe I
Thyroid; 2021 Sep; 31(9):1376-1382. PubMed ID: 33764195
[No Abstract] [Full Text] [Related]
5. Thyroid imaging reporting and data system score combined with Bethesda system for malignancy risk stratification in thyroid nodules with indeterminate results on cytology.
Maia FF; Matos PS; Pavin EJ; Zantut-Wittmann DE
Clin Endocrinol (Oxf); 2015 Mar; 82(3):439-44. PubMed ID: 24930423
[TBL] [Abstract][Full Text] [Related]
6. Gene Expression Classifier vs Targeted Next-Generation Sequencing in the Management of Indeterminate Thyroid Nodules.
Livhits MJ; Kuo EJ; Leung AM; Rao J; Levin M; Douek ML; Beckett KR; Zanocco KA; Cheung DS; Gofnung YA; Smooke-Praw S; Yeh MW
J Clin Endocrinol Metab; 2018 Jun; 103(6):2261-2268. PubMed ID: 29590358
[TBL] [Abstract][Full Text] [Related]
7. Bethesda III and IV Thyroid Nodules Managed Nonoperatively After Molecular Testing With Afirma GSC or Thyroseq v3.
Kim NE; Raghunathan RS; Hughes EG; Longstaff XR; Tseng CH; Li S; Cheung DS; Gofnung YA; Famini P; Wu JX; Yeh MW; Livhits MJ
J Clin Endocrinol Metab; 2023 Aug; 108(9):e698-e703. PubMed ID: 36995878
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the Afirma Gene Expression Classifier in Repeat Indeterminate Thyroid Nodules.
Harrison G; Sosa JA; Jiang X
Arch Pathol Lab Med; 2017 Jul; 141(7):985-989. PubMed ID: 28467214
[TBL] [Abstract][Full Text] [Related]
9. Thyroseq v3, Afirma GSC, and microRNA Panels Versus Previous Molecular Tests in the Preoperative Diagnosis of Indeterminate Thyroid Nodules: A Systematic Review and Meta-Analysis.
Silaghi CA; Lozovanu V; Georgescu CE; Georgescu RD; Susman S; Năsui BA; Dobrean A; Silaghi H
Front Endocrinol (Lausanne); 2021; 12():649522. PubMed ID: 34054725
[TBL] [Abstract][Full Text] [Related]
10. Impact of Afirma gene expression classifier on cytopathology diagnosis and rate of thyroidectomy.
Sacks WL; Bose S; Zumsteg ZS; Wong R; Shiao SL; Braunstein GD; Ho AS
Cancer Cytopathol; 2016 Oct; 124(10):722-728. PubMed ID: 27347838
[TBL] [Abstract][Full Text] [Related]
11. The Diagnostic Performance of Thyroid US in Each Category of the Bethesda System for Reporting Thyroid Cytopathology.
Park SY; Hahn SY; Shin JH; Ko EY; Oh YL
PLoS One; 2016; 11(6):e0155898. PubMed ID: 27348515
[TBL] [Abstract][Full Text] [Related]
12. ThyroSeq
Rivas AM; Nassar A; Zhang J; Casler JD; Chindris AM; Smallridge R; Bernet V
Endocr Pract; 2018 Sep; 24(9):780-788. PubMed ID: 30084677
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic performance of the second-generation molecular tests in the assessment of indeterminate thyroid nodules: A systematic review and meta-analysis.
Lee E; Terhaar S; McDaniel L; Gorelik D; Gerhard E; Chen C; Ma Y; Joshi AS; Goodman JF; Thakkar PG
Am J Otolaryngol; 2022; 43(3):103394. PubMed ID: 35241290
[TBL] [Abstract][Full Text] [Related]
14. A tertiary center's experience with second review of 3885 thyroid cytopathology specimens.
Olson MT; Boonyaarunnate T; Aragon Han P; Umbricht CB; Ali SZ; Zeiger MA
J Clin Endocrinol Metab; 2013 Apr; 98(4):1450-7. PubMed ID: 23436916
[TBL] [Abstract][Full Text] [Related]
15. Evidence for overestimation of the prevalence of malignancy in indeterminate thyroid nodules classified as Bethesda category III.
Iskandar ME; Bonomo G; Avadhani V; Persky M; Lucido D; Wang B; Marti JL
Surgery; 2015 Mar; 157(3):510-7. PubMed ID: 25633738
[TBL] [Abstract][Full Text] [Related]
16. Interinstitutional variation in predictive value of the ThyroSeq v2 genomic classifier for cytologically indeterminate thyroid nodules.
Marcadis AR; Valderrabano P; Ho AS; Tepe J; Swartzwelder CE; Byrd S; Sacks WL; Untch BR; Shaha AR; Xu B; Lin O; Ghossein RA; Wong RJ; Marti JL; Morris LGT
Surgery; 2019 Jan; 165(1):17-24. PubMed ID: 30360906
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of 167 Gene Expression Classifier (GEC) and ThyroSeq v2 Diagnostic Accuracy in the Preoperative Assessment of Indeterminate Thyroid Nodules: Bivariate/HROC Meta-analysis.
Borowczyk M; Szczepanek-Parulska E; Olejarz M; Więckowska B; Verburg FA; Dębicki S; Budny B; Janicka-Jedyńska M; Ziemnicka K; Ruchała M
Endocr Pathol; 2019 Mar; 30(1):8-15. PubMed ID: 30591992
[TBL] [Abstract][Full Text] [Related]
18. The utility of ThyroSeq
Li W; Justice-Clark T; Cohen MB
Cytopathology; 2021 Jul; 32(4):505-512. PubMed ID: 33914382
[TBL] [Abstract][Full Text] [Related]
19. Wide Inter-institutional Variation in Performance of a Molecular Classifier for Indeterminate Thyroid Nodules.
Marti JL; Avadhani V; Donatelli LA; Niyogi S; Wang B; Wong RJ; Shaha AR; Ghossein RA; Lin O; Morris LG; Ho AS
Ann Surg Oncol; 2015 Nov; 22(12):3996-4001. PubMed ID: 25862581
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneity in Positive Predictive Value of RAS Mutations in Cytologically Indeterminate Thyroid Nodules.
Nabhan F; Porter K; Lupo MA; Randolph GW; Patel KN; Kloos RT
Thyroid; 2018 Jun; 28(6):729-738. PubMed ID: 29665745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
